

CLAIMS

1. A disintegrant for tablets consisting of an  $\alpha$ -1,4-glucan having a degree of polymerization of not less than 180 and less than 1230 and a dispersity (weight average molecular weight "Mw"/number average molecular weight "Mn") of not more than 1.25 or a modified product thereof.  
5
2. The disintegrant according to claim 1, wherein said  $\alpha$ -1,4-glucan is an enzymatically synthesized  $\alpha$ -1,4-glucan.  
10
3. The disintegrant according to claim 1, wherein said disintegrant is a modified product of said  $\alpha$ -1,4-glucan, and said modification is a chemical modification selected from the group consisting of esterification, etherification and cross-linking.  
15
4. A binder for tablets consisting of an  $\alpha$ -1,4-glucan having a degree of polymerization of not less than 1230 and not more than 37000 and a dispersity of not more than 1.25 or a modified product thereof.  
20
5. The binder according to claim 4, wherein said  $\alpha$ -1,4-glucan is an enzymatically synthesized  $\alpha$ -1,4-glucan.  
25
6. The binder according to claim 4, wherein said binder is a modified product of said  $\alpha$ -1,4-glucan, and said modification is a chemical modification selected from the group consisting of esterification, etherification and cross-linking.  
30
7. A binding-disintegrating agent for tablets consisting of a low molecular weight  $\alpha$ -1,4-glucan or a modified product

thereof, and a high molecular weight  $\alpha$ -1,4-glucan or a modified product thereof,

5 wherein said low molecular weight  $\alpha$ -1,4-glucan has a degree of polymerization of not less than 180 and less than 1230 and a dispersity of not more than 1.25, and

wherein said high molecular weight  $\alpha$ -1,4-glucan has a degree of polymerization of not less than 1230 and less than 37000 and a dispersity of not more than 1.25.

10 8. The binding-disintegrating agent according to claim 7, wherein said  $\alpha$ -1,4-glucan is an enzymatically synthesized  $\alpha$ -1,4-glucan.

15 9. The binding-disintegrating agent according to claim 7, wherein said binding-disintegrating agent is a modified product of said  $\alpha$ -1,4-glucan, and said modification is a chemical modification selected from the group consisting of esterification, etherification and cross-linking.

20 10. The binding-disintegrating agent according to claim 7, wherein the weight ratio of said low molecular weight  $\alpha$ -1,4-glucan or a modified product thereof to said high molecular weight  $\alpha$ -1,4-glucan or a modified product thereof is 98:2 to 60:40.

25 11. The binding-disintegrating agent according to claim 7, wherein the weight ratio of said low molecular weight  $\alpha$ -1,4-glucan or a modified product thereof to said high molecular weight  $\alpha$ -1,4-glucan or a modified product thereof is 2:98 to 40:60.

30 12. A tablet comprising a low molecular weight  $\alpha$ -1,4-glucan or a modified product thereof, and a high molecular weight

$\alpha$ -1,4-glucan or a modified product thereof,

wherein said low molecular weight  $\alpha$ -1,4-glucan has a degree of polymerization of not less than 180 and less than 1230 and a dispersity of not more than 1.25, and

5 wherein said high molecular weight  $\alpha$ -1,4-glucan has a degree of polymerization of not less than 1230 and less than 37000 and a dispersity of not more than 1.25.